Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial
Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results.
The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly.
This marks the first successful late-stage trial for an mRNA cancer vaccine.
The findings offer hope for future growth beyond COVID-19 vaccines.
Discussions with regulators are expected within the next few months.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on economictimes.indiatimes.com — the content belongs to The Economic Times.
